24 recruiting, 7 not yet recruiting, 4 completed, 3 unknown. 11 Phase 1, 9 Phase 2, 7 Not applicable, 7 Phase 3, 2 Early Phase 1.
Follow PDAC - Pancreatic Ductal Adenocarcinoma: new trials by email Literature Review of PDAC - Pancreatic Ductal Adenocarcinoma trials Research Report on PDAC - Pancreatic Ductal Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma | Phase 1 / Phase 2 | Withdrawn | Lisata Therapeutics, Inc. | 2030-01-01 | 2025-06-06 | |
| IKS04 Regimen in Advanced Solid Tumors That Express CA242 IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody - Colorectal Cancer, Gastro Esophageal Junctional Cancer | Phase 1 | Not yet recruiting | Iksuda Therapeutics Ltd. | 120 | 2026-11-01 | 2026-07-31 |
| Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma Avutometinib (VS-6766) + Defactinib (VS-6063) - Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | University of Virginia | 31 | 2026-10-01 | 2026-09-17 |
| Exploratory Clinical Evaluation of Personalized Functional Profiling in GI Tumors: Predicting Drug Response in CRC and PDAC Personalized Functional Profiling - Colorectal Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Recruiting | Luxembourg Institute of Health | 188 | 2026-09-11 | 2026-09-15 | |
| Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage I | Not yet recruiting | Immunovia, Inc. | 400 | 2026-09-01 | 2026-09-04 | |
| Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma | Early Phase 1 | Not yet recruiting | Lumina Pharmaceuticals Inc | 40 | 2026-09-01 | 2026-08-28 |
| Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 400 | 2026-08-28 | 2026-10-16 |
| Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Atebimetinib, GnP, mGnP - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Immuneering Corporation | 510 | 2026-06-05 | 2026-10-16 |
| Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 ) Zoldonrasib, Placebo, Oxaliplatin - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 670 | 2026-05-22 | 2026-10-13 |
| The Canopy Cancer Collective Clinical Registry Protocol Gastrointestinal Neoplasms, Pancreatic Cancer | Not yet recruiting | Canopy Cancer Collective, LLC | 100000 | 2026-05-01 | 2026-05-26 | |
| AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors AVA6103 - Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Avacta Life Sciences Ltd | 174 | 2026-03-31 | 2026-10-05 |
| Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma daraxonrasib, gemcitabine, nab-paclitaxel - Pancreatic Cancer, Pancreatic Cancer Metastatic | Phase 3 | Recruiting | Revolution Medicines, Inc. | 900 | 2026-03-09 | 2026-10-02 |
| A Phase III, Randomized, Clinical Trial of GnP Combined With SBRT and Serplulimab Versus GnP as First-Line Treatment for Patients With Recurrent or Metastatic Pancreatic Cancer (WGOG-PAN 006/ICSBR-2) GnP, SBRT, Serplulimab - PDAC - Pancreatic Ductal Adenocarcinoma | Phase 3 | Not yet recruiting | West China Hospital | 198 | 2026-02-01 | 2026-01-13 |
| A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer E-EDV-D682, EDV-GC, Gemcitabine - Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Engeneic Pty Limited | 144 | 2026-01-12 | 2026-02-27 |
| Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) daraxonrasib - Pancreatic Cancer, PDAC | Phase 3 | Recruiting | Revolution Medicines, Inc. | 500 | 2025-12-15 | 2026-09-23 |
| Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) Breath test - Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Recruiting | Imperial College London | 6079 | 2025-10-21 | 2026-07-09 | |
| PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma PDAC-PATHWAYS, Usual Care - PDAC - Pancreatic Ductal Adenocarcinoma | Not applicable | Recruiting | Massachusetts General Hospital | 50 | 2025-10-06 | 2026-07-29 |
| Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA) HOP bundle - Pancreas Head Cancer, Pancreas Adenocarcinoma | Phase 4 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 400 | 2025-09-01 | 2025-12-22 |
| Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer Diagnostic procedures - Diabetes, IPMN, Pancreatic | Not applicable | Recruiting | Fondazione Policlinico Universitario Campus Bio-Medico | 400 | 2025-09-01 | 2026-06-22 |
| Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer Diagnostic Evaluation for Positive AI Findings - Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm | Recruiting | Changhai Hospital | 400000 | 2025-08-15 | 2025-08-12 |
Showing 20 of 45. Sign in to see all of them.
Pancreatic Neoplasms (24) · Colorectal Neoplasms (8) · Neoplasm Metastasis (5) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (3) · Stomach Neoplasms (3) · Biliary Tract Neoplasms (2) · Neoplasms (2) · Pancreatic Intraductal Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Carcinoma (1) · Cholangiocarcinoma (1) · Colonic Neoplasms (1) · Diabetes Mellitus (1)
Digestive System Diseases (33) · Digestive System Neoplasms (32) · Neoplasms by Site (32) · Neoplasms (31) · Pancreatic Diseases (27) · Endocrine Gland Neoplasms (26) · Endocrine System Diseases (26) · Gastrointestinal Diseases (10) · Gastrointestinal Neoplasms (9) · Intestinal Diseases (9) · Intestinal Neoplasms (9) · Colonic Diseases (8) · Pathological Conditions, Signs and Symptoms (8) · Rectal Diseases (8) · Pathologic Processes (7)
Gemcitabine (10) · 130-nm albumin-bound paclitaxel (9) · Blood Specimen Collection (3) · Fluorouracil (3) · Leucovorin (3) · Oxaliplatin (3) · Breath Tests (2) · Carboplatin (2) · Cetuximab (2) · Cisplatin (2) · Irinotecan (2) · Pemetrexed (2) · camrelizumab (2) · irinotecan sucrosofate (2) · pembrolizumab (2)
Revolution Medicines, Inc. (6) · Azienda Ospedaliera Universitaria Integrata Verona (2) · Immunovia, Inc. (2) · Imperial College London (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Alterome Therapeutics, Inc. (1) · Avacta Life Sciences Ltd (1) · British Columbia Cancer Agency (1) · Canopy Cancer Collective, LLC (1) · Cedars-Sinai Medical Center (1) · Changhai Hospital (1) · Chinese PLA General Hospital (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Engeneic Pty Limited (1)
United States (25) · Italy (7) · China (6) · United Kingdom (6) · France (4) · Germany (4) · Australia (3) · Canada (3) · Japan (3) · Netherlands (3) · Puerto Rico (3) · Spain (3) · South Korea (2) · Austria (1) · Belgium (1)
Professor George B Hanna, PhD, FRCS (2) · Ajay Goel, PhD (1) · Binbin Zheng, MD (1) · Daniel Renouf, MD, MPH (1) · Dr Himanshu Brahmbhatt, Ph.D (1) · Dr Jennifer MacDiarmid, Ph.D (1) · Dr Linda Y.Wu, MD (1) · Eileen O'Reilly, MD (1) · Henkjan Huisman, MSc, PhD (1) · James O'Leary, MD (1) · Jihui Hao, Dr. (1) · John Hermans, MSc, MD, PhD (1) · Kristen K. Buck, MD (1) · Lodewijk Brosens (1)
PMID 38011131, PMID 40866056, PMID 41077611, PMID 41790032, PMID 42223072
R44CA275590 (1)